TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03626233

Intervention type: OTHER
Intervention: collect of placenta, blood and urinary samples at delivery
Description: collect of placenta, blood and urinary samples at delivery

Intervention type: OTHER
Intervention: collect of placenta, blood and urinary samples at delivery
Description: collect of placenta, blood and urinary samples at delivery
Study: NCT04445103

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of cardiac function
Description: Echocardiographic examination and assessment of cardiac biomakers

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of cardiac function
Description: Echocardiographic examination and assessment of cardiac biomakers

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of cardiac function
Description: Echocardiographic examination and assessment of cardiac biomakers
Study: NCT00614224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill exercise training
Description: 3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treadmill exercise training
Description: 3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
Study: NCT01631266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 T.U. Tuberculin PPD RT 23 SSI
Description: The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Study: NCT03197519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCApp
Description: During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
Study: NCT02458599

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference product 1
Description: Iso-energetic carbohydrate (20 g)
Study: NCT01478425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipidic Microemulsion
Description: Topical nasal, twice a day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Topical Nasal, twice a day
Study: NCT02458599

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reference product 2
Description: Negligible energy placebo (20 g)
Study: NCT04767828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYRROTINI
Description: CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain radiation therapy
Description: Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
Study: NCT02081898

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCD
Description: approximate 100 kcal/d caloric deficit
Study: NCT00942149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: single dose of 6 mg/kg of daptomycin
Study: NCT01988233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAILAMOS© Dance Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Control Group
Study: NCT04369534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Administration of standard dose of ticagrelor during 12 months after PCI
Study: NCT03621761

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
Study: NCT02637908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: 6-weeks of group-based mindfulness training for parents
Study: NCT01144650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
Study: NCT02178540

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one dose (4 capsules) of placebo

Intervention type: DEVICE
Group type: OTHER
Intervention: Tobi Podhaler
Description: The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
Study: NCT00869037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection
Description: A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CFNB + Posterior Capsular Injection
Description: A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
Study: NCT03013348

Intervention type: DEVICE
Intervention: Brain Sentinel's sEMG Post-processing algorithm
Description: Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.

Intervention type: DEVICE
Intervention: Brain Sentinel's sEMG Post-processing algorithm
Description: Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.

Intervention type: DEVICE
Intervention: Brain Sentinel's sEMG Post-processing algorithm
Description: Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.
Study: NCT00819819

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
Study: NCT03694678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovering Together
Description: The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
Study: NCT03178994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Description: 2% ketoconazole cream applies twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrophilic Cream
Description: Hydrophilic cream (in-house preparation) applies twice daily
Study: NCT01955668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of AZD6738
Description: An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
Study: NCT01048463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutriall
Description: The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutriall
Description: The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
Study: NCT01144650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
Study: NCT03594708

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition supplement
Description: Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: rice starch, light olive oil, vegetable oil
Study: NCT00646230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT03739619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03663582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
Study: NCT00074204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT03663582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial Adapter for Device
Description: Vial adapter for device is approved for use in Japan by PMDA.
Study: NCT00693758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine
Description: intravenous infusion of adenosine (140microgr./min/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine
Description: intravenous infusion of adenosine (140microgr./min/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified end-tidal forcing system
Description: changes in partial pressures of O2 and CO2 in inspired air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified end-tidal forcing system
Description: changes in partial pressures of O2 and CO2 in inspired air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm cuff occlusion
Description: 3 min. lasting upper arm cuff occlusion

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Breathing gas
Description: Changes in pO2 and pCO2 in inspired air mix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure cuff
Description: supra-systolic arm occlusion with pressure cuff
Study: NCT03416816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0337
Description: DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
Study: NCT01179373

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TMS, H coil
Description: TMS, H Coil, High/ Low Frequency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS, H coil
Description: TMS, H Coil, High/ Low Frequency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS, H coil
Description: TMS, H Coil, High/ Low Frequency
Study: NCT01335607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Samatasvir tablet
Description: Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Samatasvir tablet
Description: Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Samatasvir capsule
Description: Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Samatasvir capsule
Description: Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
Study: NCT03367104

Intervention type: DEVICE
Intervention: ECG Belt
Description: Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.

Intervention type: DEVICE
Intervention: ECG Belt
Description: Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
Study: NCT00074204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04306926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Give according to the location of the lesion and clinical condition.
Study: NCT03094052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given orally (PO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenoxylate Hydrochloride/Atropine Sulfate
Description: Given PO
Study: NCT01151267

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Anesthesia management for post surgical patients
Description: The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypercarbic Spontaneous Hyperpnoea
Description: Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
Study: NCT02672995

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery
Description: Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab.
Study: NCT04388826

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Veru-111
Description: Respiratory Distress Syndrome, Adult

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veru-111
Description: Respiratory Distress Syndrome, Adult
Study: NCT04816032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pennebaker's expressive writing intervention
Description: It focuses on the emotional aspect of the written event

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral writing
Description: Description of neutral topics with less emotional involvement
Study: NCT02972645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03218865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIE high flux dialyzer
Description: Asssesment of the therapeutic effect of the vitamin E coating

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leoceed H high flux dialyzer
Description: Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
Study: NCT02458235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
Study: NCT00895921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Single intramuscular 10-mg dose
Study: NCT02425254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: 1000mg intravenous solution for infusion
Study: NCT00895921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Single intramuscular 9.75-mg dose
Study: NCT02437318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpelisib placebo
Study: NCT02001168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh-Endostatin
Description: rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.